How effective is Belzutifan in treating pheochromocytoma?

Belzutifan As a selective hypoxia-inducible factor-2α (HIF-2α) inhibitor, it has attracted widespread attention in the treatment of various solid tumors in recent years, especially in the treatment of pheochromocytoma and paraganglioma (PPGL), showing promising efficacy. Pheochromocytoma and paraganglioma are rare neuroendocrine tumors originating from neural crest tissue. They have the property of secreting catecholamines and often cause refractory hypertension and multi-system clinical manifestations. Traditional treatment methods such as surgery, radiotherapy or chemotherapy often have limited effects in locally advanced or metastatic stages, and new systemic treatment options are urgently needed. The mechanism of action of Bestifan cuts into the molecular pathological basis of this type of tumor. Especially in the context of VHL pathway imbalance, its inhibition of HIF-2α can significantly affect the metabolism, proliferation and angiogenesis of tumor cells.

In theLITESPARK-015 study, bestivan was used to treat patients with locally advanced or metastatic PPGL. This is the first time the FDA has recognized a pivotal study for this indication. Research data shows that the drug achieved an objective response rate (ORR) of 26% in a population with limited previous treatment options, which means that more than a quarter of patients have achieved a considerable reduction in tumor size. More importantly, the response produced by the treatment has a longer duration, with a median response period of 20.4 months, which is particularly important for patients with high tumor burden or functionally active tumors. The study also observed that the drug may bring functional relief, that is, some patients can significantly reduce their hypertension medication, which has positive significance for improving quality of life.

In addition, besetifan is an oral preparation with good compliance and low intervention, making it more potential for promotion in clinical practice. Although there is still room for improvement in its objective response rate, its significance cannot be underestimated compared with the lack of standard systemic treatment in the past.

References:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma